Lurbinectedin Composition and Methods Making the Same
AssigneePharma Mar, S.A.
InventorsPilar Calvo, Maria Tobio
Life of this patent
Estimating the term…
Abstract
Provided are methods for the treatment of SCLC patients by administering therapeutic amounts of lurbinectedin by intravenous infusion. Also provided are methods of treating cancer by administering lurbinectedin in combination with other anticancer drugs, in particular topoisomerase inhibitors. The invention further relates to the administration of lurbinectedin in combination with anti-emetic agents for effective control of symptoms related to nausea and vomiting, reduced lurbinectedin dosages to achieve a safer administration and an increase in the number of treatment cycles. Stable lyophilized formulations of lurbinectedin are also provided.
Claims14
A pharmaceutical composition comprising lurbinectedin, a buffer derived from an organic carboxylic acid and a disaccharide, wherein the composition is lyophilized and comprises no more than 0.8% wt/wt of deacetylated lurbinectedin based on the total weight of lurbinectedin.
Dependencies are inferred from the claim text.